Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

用纹状体多巴胺能缺乏的测量预测帕金森病的神经精神症状

卷 18, 期 6, 2021

发表于: 27 August, 2021

页: [499 - 504] 页: 6

弟呕挨: 10.2174/1567205018666210827122133

价格: $65

conference banner
摘要

背景：黑质纹状体多巴胺能神经元变性在帕金森病的病理生理学中的作用已得到公认。然而，目前尚不清楚多巴胺通路的退化是否以及如何影响帕金森病 (PD) 的神经精神症状 (NPS) 的表现。多巴胺转运蛋白 (DAT) 成像是一种测量多巴胺转运蛋白减少的技术，越来越多地用作诊断 PD 的工具。 方法：在这项研究中，我们检查了纹状体结合率 (SBR) 测量的纹状体中基线多巴胺转运蛋白密度是否与运动障碍协会第 1 部分测量的 PD 中 NPS 的纵向发作和/或进展相关 -统一帕金森病评定量表，四年多。 PD 患者的数据和 123I-碘氟烷单质子发射计算机断层扫描的异常筛查数据来自帕金森病进展标志物倡议 (PPMI) 数据库。潜在增长模型 (LGM) 是一种统计技术，可以对随时间的变化进行建模，同时考虑个体水平变化率的可变性，用于检查 NPS 随时间的进展。 结果：结果表明 SBR 与基线 NPS 无关，但与 NPS 的变化率（p<0.001）在接下来的四年中相关，即使在消除了年龄相关的方差之后，这可能是一个重要的混杂因素。 结论：总而言之，这项研究表明帕金森病患者的 NPS 逐渐恶化，这与基线时 SBR 测量的多巴胺转运蛋白密度呈负相关。

关键词: 神经精神症状、帕金森病、多巴胺、纹状体、神经影像学、潜在生长模型。

« Previous Next »
[1]
Weintraub D, Mamikonyan E. The neuropsychiatry of Parkinson disease: A perfect storm. Am J Geriatr Psychiatry 2019; 27(9): 998-1018.
[http://dx.doi.org/10.1016/j.jagp.2019.03.002] [PMID: 31006550]
[2]
Weintraub D, Simuni T, Caspell-Garcia C, et al. Initiative PsPM. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 2015; 30(7): 919-27.
[http://dx.doi.org/10.1002/mds.26170] [PMID: 25737166]
[3]
Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009; 80(8): 928-30.
[http://dx.doi.org/10.1136/jnnp.2008.166959] [PMID: 19608786]
[4]
Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 2009; 24(16): 2391-7.
[http://dx.doi.org/10.1002/mds.22843] [PMID: 19908317]
[5]
Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55(5): 377-82.
[http://dx.doi.org/10.1136/jnnp.55.5.377] [PMID: 1602311]
[6]
Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann Neurol 1989; 26(4): 551-7.
[http://dx.doi.org/10.1002/ana.410260409] [PMID: 2817829]
[7]
Isaacson SH, Fisher S, Gupta F, et al. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother 2017; 17(3): 219-25.
[http://dx.doi.org/10.1080/14737175.2017.1256205] [PMID: 27813429]
[8]
Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 2010; 39(1): 98-104.
[http://dx.doi.org/10.1016/j.nbd.2010.03.013] [PMID: 20338240]
[9]
Santangelo G, Vitale C, Picillo M, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord 2015; 21(5): 489-93.
[http://dx.doi.org/10.1016/j.parkreldis.2015.02.015] [PMID: 25753457]
[10]
Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 2009; 24(14): 2097-103.
[http://dx.doi.org/10.1002/mds.22702] [PMID: 19705471]
[11]
Ye BS, Jeon S, Yoon S, et al. Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 2018; 89(2): 197-204.
[http://dx.doi.org/10.1136/jnnp-2017-316075] [PMID: 28951497]
[12]
Erro R, Pappatà S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord 2012; 18(9): 1034-8.
[http://dx.doi.org/10.1016/j.parkreldis.2012.05.022] [PMID: 22789824]
[13]
Felicio AC, Moriyama TS, Godeiro-Junior C, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology (Berl) 2010; 211(1): 27-31.
[http://dx.doi.org/10.1007/s00213-010-1867-y] [PMID: 20495790]
[14]
Goetz CG, Tilley BC, Shaftman SR, et al. Force MDSURT. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23(15): 2129-70.
[http://dx.doi.org/10.1002/mds.22340] [PMID: 19025984]
[15]
Hess B. Assessing program impact using latent growth modeling: a primer for the evaluator. Eval Program Plann 2000; 23: 419-28.
[http://dx.doi.org/10.1016/S0149-7189(00)00032-X]
[16]
Choi Y, Golder S, Gillmore MR, Morrison DM. Analysis with missing data in social work research. J Soc Serv Res 2005; 31: 23-48.
[http://dx.doi.org/10.1300/J079v31n03_02]
[17]
Jöreskog KG, Sörbom D. LISREL 8: Structural equation modeling with the SIMPLIS command language. Scientific Software International 1993.
[18]
Hu L-t, Bentler PM. Fit indices in covariance structure modeling: Sensitivity to underparameterized model misspecification. Psychol Methods 1998; 3: 424.
[http://dx.doi.org/10.1037/1082-989X.3.4.424]
[19]
Cole JH, Marioni RE, Harris SE, Deary IJ. Brain age and other bodily ‘ages’: implications for neuropsychiatry. Mol Psychiatry 2019; 24(2): 266-81.
[http://dx.doi.org/10.1038/s41380-018-0098-1] [PMID: 29892055]
[20]
Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 2014; 85(2): 159-64.
[http://dx.doi.org/10.1136/jnnp-2012-304811] [PMID: 23813742]
[21]
Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease. Mov Disord 2012; 27(11): 1392-7.
[http://dx.doi.org/10.1002/mds.25157] [PMID: 22976926]
[22]
Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2005; 46(2): 227-32.
[PMID: 15695780]
[23]
Park SB, Kwon KY, Lee JY, et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci 2019; 40(2): 311-7.
[http://dx.doi.org/10.1007/s10072-018-3632-7] [PMID: 30415448]
[24]
Yousaf T, Pagano G, Niccolini F, Politis M. Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2). J Neurol 2019; 266(5): 1203-10.
[http://dx.doi.org/10.1007/s00415-019-09250-y] [PMID: 30820739]
[25]
Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167(7): 748-51.
[http://dx.doi.org/10.1176/appi.ajp.2010.09091379] [PMID: 20595427]
[26]
Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry 2014; 171(4): 395-7.
[http://dx.doi.org/10.1176/appi.ajp.2014.14020138] [PMID: 24687194]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy